Clinical application of vacuum-assisted cardiopulmonary bypass with a pressure relief valve.

[1]  H. Matsuda,et al.  Controlled Nicorandil Administration for Myocardial Protection During Coronary Artery Bypass Grafting Under Cardiopulmonary Bypass , 2001, Journal of cardiovascular pharmacology.

[2]  根本 慎太郎.  Free hemoglobin impairs cardiac function in neonatal rabbit hearts , 2001 .

[3]  S. Büket,et al.  The effects of modified hemofiltration on inflammatory mediators and cardiac performance in coronary artery bypass grafting , 2000, Perfusion.

[4]  Schmucker,et al.  Perioperative serum levels of tumour‐necrosis‐factor alpha (TNF‐α), IL‐1β, IL‐6, IL‐10 and soluble IL‐2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution , 1999, Clinical and experimental immunology.

[5]  D. Sharpe,et al.  Haemolysis during cardiopulmonary bypass: an in vivo comparison of standard roller pumps, nonocclusive roller pumps and centrifugal pumps , 1999, Perfusion.

[6]  D. Cosgrove,et al.  Minimally invasive valve operations. , 1998, The Annals of thoracic surgery.

[7]  H. Matsuda,et al.  A novel technique for cardiopulmonary bypass using vacuum system for venous drainage with pressure relief valve: an experimental study. , 1998, Artificial organs.

[8]  S. Gundry,et al.  Facile minimally invasive cardiac surgery via ministernotomy. , 1998, The Annals of thoracic surgery.

[9]  T. Burdon,et al.  Closed-chest cardiopulmonary bypass and cardioplegia: basis for less invasive cardiac surgery. , 1997, The Annals of thoracic surgery.

[10]  L. Foubert,et al.  Low extracorporeal priming volumes for infants: a benefit? , 1996, Perfusion.

[11]  A. Galloway,et al.  Minimally invasive cardiopulmonary bypass with cardioplegic arrest: a closed chest technique with equivalent myocardial protection. , 1996, The Journal of thoracic and cardiovascular surgery.

[12]  R. S. Mitchell,et al.  Port-access coronary artery bypass grafting: a proposed surgical method. , 1996, The Journal of thoracic and cardiovascular surgery.

[13]  H. Matsuda,et al.  Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. , 1996, The Journal of thoracic and cardiovascular surgery.

[14]  C. Wildevuur,et al.  Reduction in prime volume attenuates the hyperdynamic response after cardiopulmonary bypass. , 1995, The Annals of thoracic surgery.

[15]  A. Galloway,et al.  Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. , 1995 .

[16]  G. Tangen,et al.  Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. , 1995, The Annals of thoracic surgery.

[17]  T. Spyt,et al.  Release of vasoactive substances during cardiopulmonary bypass. , 1993, Annals of Thoracic Surgery.

[18]  P. Venge,et al.  Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. A clinical study. , 1992, The Journal of thoracic and cardiovascular surgery.

[19]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, The Journal of thoracic and cardiovascular surgery.

[20]  E. Garnett,et al.  Albumin and water fluxes during cardiopulmonary bypass. , 1974, The Journal of thoracic and cardiovascular surgery.